Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
NCT03230786
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
255
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:
Daily injection of KBP/placebo for 12 weeks as add-on to metformin
Sponsor
KeyBioscience AG
Collaborators
[object Object]